Sanofi Signs Deal with Principia to Strengthen its Position in Multiple Sclerosis

By Natasha Piper

Pharma Deals Review: Vol 2017 Issue 11 (Table of Contents)

Published: 22 Nov-2017

DOI: 10.3833/pdr.v2017.i11.2286     ISSN: 1756-7874

Section: Licensing



Sanofi has promised up to US$805 M to Principia Biopharma in return for licensing global rights to a Phase I drug that has potential in the treatment of multiple sclerosis (MS) and other neurological disorders...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details